Anika Therapeutics Inc Stock Price, News & Analysis

Anika Therapeutics, a global joint preservation company, will host its 2021 Virtual Investor Day on June 3, 2021, starting at 9:00 AM EDT. Key executives, including President Cheryl Blanchard and CFO Mike Levitz, will present an overview of the company's business strategy, product portfolio, R&D pipeline, and financial objectives. The event will feature presentations followed by a Q&A session with senior leaders. A webcast will be available on the company’s Investor Relations website for replay.

Anika Therapeutics reported Q1 2021 revenue of $34.3 million, down 3% year-over-year. Joint Preservation revenue surged 55% to $12.2 million, driven by acquisitions, while Joint Pain Management dropped 24% to $19.3 million, mainly due to COVID impacts. The company's revenue mix is shifting positively, with Joint Preservation now 36% of total revenue. Net income fell to $2.8 million ($0.20 per share) versus $5.8 million ($0.40 per share) last year. For 2021, Anika expects upper 20% to low 30% growth in Joint Preservation, projecting overall revenue growth in the high single to low double digits.

Anika Therapeutics (NASDAQ: ANIK) announced participation in three upcoming virtual investor conferences this May. Dr. Cheryl Blanchard, CEO, and Michael Levitz, CFO, will present at the following events: the 16th Annual Canaccord Genuity Musculoskeletal Conference on May 20, starting at 9:00 a.m. ET, the UBS Global Healthcare Virtual Conference on May 25, starting at 8:00 a.m. ET, and Oppenheimer’s MedTech Summit with a pre-recorded session on May 26. All presentations will be accessible via Anika's Investor Relations website.

Anika Therapeutics (NASDAQ: ANIK) plans to release its first quarter 2021 financial results on May 6, 2021, after market close. Following the release, the company will hold an investor conference call at 5:00 p.m. ET to discuss financials and business updates. Interested parties can access the call by phone or through a live audio webcast available on Anika's Investor Relations webpage. Anika specializes in joint preservation and minimally invasive orthopedic solutions, focusing on areas like osteoarthritis pain management and regenerative therapies.

Anika Therapeutics (NASDAQ: ANIK) has announced that Dr. Cheryl Blanchard, President and CEO, and Michael Levitz, CFO, will present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 3:45 p.m. ET. The event will be accessible via a live audio webcast on Anika's Investor Relations website, and an audio archive will be available post-event.

As a leader in joint preservation, Anika focuses on developing innovative orthopedic solutions for osteoarthritis and soft tissue repair, enhancing patient outcomes and active living.

Anika Therapeutics, a joint preservation company, will present at the Sidoti Spring Virtual Investor Conference on March 25, 2021, at 8:30 a.m. ET. The presentation will feature Dr. Cheryl Blanchard, President and CEO, alongside Michael Levitz, Executive Vice President and CFO. A live audio webcast will be available on Anika’s website, with an archive accessible later. Anika focuses on innovative orthopedic solutions, including osteoarthritis management and regenerative treatments.

Anika Therapeutics reported a 10% revenue increase in Q4 2020, totaling $32.7 million, and a 14% increase in full-year revenue to $130.5 million. The growth stemmed from joint preservation products following two acquisitions. However, the company faced a net loss of $15.7 million in Q4, attributed to goodwill impairment and acquisition-related expenses. Adjusted net income for the quarter was $1.7 million. For 2021, Anika is not providing detailed financial guidance due to ongoing COVID-19 uncertainties.

Anika Therapeutics (NASDAQ: ANIK) will release its fourth quarter and year-end 2020 financial results after market close on March 4, 2021. An investor conference call will follow at 5:00 p.m. ET to discuss these results and business highlights. Interested parties can access the call by dialing the provided numbers or via a live audio webcast available on Anika's Investor Relations page. The call will be archived for later access.

Anika Therapeutics reported a 7% increase in revenue year-over-year, totaling $31.7 million for Q3 2020, driven by its orthopedics segment and recent acquisitions. Despite this growth, the company experienced a net loss of $6.4 million, or $0.45 per diluted share, compared to net income of $9.2 million in the prior year. Cash and investments fell to $124.8 million due to significant acquisition costs. The firm is expanding its product portfolio and has resumed key clinical trials, aiming for sustainable growth despite challenges from COVID-19.